Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Cas Properties LLC holds 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. The prosecution of these matters involves 2 distinct examiners and 2 distinct art units. This structure indicates that the current workload is fully decentralized across the patent office staff, with no single examiner or art unit overseeing all active matters.
RZECZYCKI, PHILLIP MATTHEW is the busiest examiner with 1 busiest examiner pending office action. The involvement of 2 distinct art units requires the applicant to navigate different examination standards and potentially different technical interpretations within the pharmaceutical field. Because there are 2 distinct examiners, the company must adapt its advocacy to the specific preferences of each individual rather than relying on a single point of contact. This decentralized approach across 2 distinct art units suggests a varied technical focus within the 2 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18142751 | ERIODICTYOL COMPOSITIONS AND METHODS | RZECZYCKI, PHILLIP MATTHEW | 11d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18142751 | ERIODICTYOL COMPOSITIONS AND METHODS | RZECZYCKI, PHILLIP MATTHEW | 11d overdue |
| 18006902 | NOBILETIN COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF COVID-19 AND RELATED PATHOLOGIES | WELLS, LAUREN QUINLAN | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18142751 | ERIODICTYOL COMPOSITIONS AND METHODS | RZECZYCKI, PHILLIP MATTHEW | 1625 | §102§103 | Final Rejection | 11d overdue | Pending | May 03, 2023 |
| 18006902 | NOBILETIN COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF COVID-19 AND RELATED PATHOLOGIES | WELLS, LAUREN QUINLAN | 1622 | §103 | Final Rejection | — | Pending | Jan 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial